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Ex vivo metabolite profiling of 
paediatric central nervous system 
tumours reveals prognostic markers
Christopher D. Bennett1,2, Simrandip K. Gill1,2, Sarah E. Kohe1,2, Martin P. Wilson3, 
Nigel P. Davies4, Theodoros N. Arvanitis  1,2,5, Daniel A. Tennant  6 & Andrew C. peet  1,2
Brain tumours are the most common cause of cancer death in children. Molecular studies have greatly 
improved our understanding of these tumours but tumour metabolism is underexplored. Metabolites 
measured in vivo have been reported as prognostic biomarkers of these tumours but analysis of 
surgically resected tumour tissue allows a more extensive set of metabolites to be measured aiding 
biomarker discovery and providing validation of in vivo findings. In this study, metabolites were 
quantified across a range of paediatric brain tumours using 1H-High-Resolution Magic Angle Spinning 
nuclear magnetic resonance spectroscopy (HR-MAS) and their prognostic potential investigated. 
HR-MAS was performed on pre-treatment frozen tumour tissue from a single centre. Univariate 
and multivariate Cox regression was used to examine the ability of metabolites to predict survival. 
The models were cross validated using C-indices and further validated by splitting the cohort into 
two. Higher concentrations of glutamine were predictive of a longer overall survival, whilst higher 
concentrations of lipids were predictive of a shorter overall survival. These metabolites were predictive 
independent of diagnosis, as demonstrated in multivariate Cox regression models. Whilst accurate 
quantification of metabolites such as glutamine in vivo is challenging, metabolites show promise as 
prognostic markers due to development of optimised detection methods and increasing use of 3 T 
clinical scanners.
Cancer is a major cause of death from disease in childhood, and brain tumours are the most common cause of 
cancer-related death in this age group1. Whilst some brain tumours now have a very good prognosis, others have 
continued to present a challenge, highlighting the need for new techniques for investigation and management. 
Identifying novel biomarkers of prognosis would allow more accurate treatment stratification to improve survival 
rates and reduce long-term morbidity. A key strategy in optimizing the clinical management of children with 
brain tumours is to identify subgroups that have prognostic significance, and this has been particularly success-
ful in medulloblastoma where molecular subgroups have already been incorporated into the accepted diagnos-
tic classification2. Whilst most molecular markers have been defined by tumour genetics, there is an increasing 
interest in tumour metabolism as both a biomarker of prognosis and potential therapeutic target. Mutations in 
the metabolic enzyme isocitrate dehydrogenase (IDH) act as a marker of good prognosis in gliomas3 and has led 
to novel therapeutic targets being identified4. The mutated enzyme produces the metabolite 2-hydroxyglutarate 
which can be detected both in tissue and in vivo providing a non-invasive test for this subgroup illustrating a key 
advantage for metabolite biomarkers of prognosis.
Whilst the identification of specific prognostic subgroups has advantages, markers that are applicable across 
multiple tumour types also give clinical value. Histological markers, such as Ki67 proliferation index, are used 
regardless of diagnosis to assess tumour aggressiveness, and MYC status is a marker of poor prognosis used clin-
ically in many different tumour types5. Specific metabolites have been proposed as markers of prognosis over a 
range of different children’s brain tumours using in vivo Magnetic Resonance Spectroscopy (MRS). Specifically, 
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glutamine and N-acetylaspartate (NAA) were found to be markers of good prognosis whilst scyllo-inositol and 
mobile lipids markers of poor prognosis6.
However, performing MRS on typical clinical scanners is associated with a number of limitations, in particu-
lar, the relatively small number of metabolites that can be measured accurately and the requirement for sampling 
of relatively large tumour volumes. Ex-vivo 1H-High-Resolution Magic Angle Spinning (HR-MAS) can ana-
lyse small brain tumour tissue samples to provide quantitative information on a larger number of metabolites7. 
HR-MAS has identified prognostic metabolic markers in a number of tumour types including prostate8, colorec-
tal9, breast10, neuroblastoma11 and pancreatic adenocarcinomas12. A good agreement has been demonstrated 
between in vivo and ex vivo methods13,14, providing an indication that HR-MAS-visible metabolites accurately 
reflect the values present in situ and are potentially observable in vivo. The primary aim of this study was to iden-
tify and measure the concentrations of metabolites in a range of paediatric brain tumours using HR-MAS and test 
the ability of metabolites to predict survival.
Methods
Patients. All patients with brain tumours presenting at the Birmingham Children’s Hospital were eligible 
to be entered into the study. Approval was obtained from the research ethics committee (NRES East Midlands-
Derby, 04/MRE04/41) and informed consent was given by parents/guardians. All experiments were performed in 
accordance with relevant guidelines and regulations. Patients were accrued between January 1998 and May 2016 
and followed up until September 2017. A consensus diagnosis was obtained for each patient by a multidiscipli-
nary team of clinicians that included histopathological diagnosis according to Louis et al.15. Brain tumour tissue, 
frozen as soon as possible after resection, was requested from the histopathology tissue bank at Birmingham 
Children’s Hospital. In total, 133 brain tumour samples were released for HR-MAS. Dates of death and clinical 
information were obtained from the West Midlands Regional Children’s Tumour Registry. Patients were treated 
with the protocol appropriate for their respective diagnosis. Broadly, this involved maximal safe surgical resection 
when the tumour was in a favourable location, with adjuvant radiotherapy and/or chemotherapy if necessary.
From the 133 tumour samples available, 19 were excluded from the analysis due to quality reasons or cause 
of death not being from the tumour diagnosis. The final cohort consisted of 114 primary pre-treatment brain 
tumour samples including 36 pilocytic astrocytomas (PA), 32 medulloblastomas (MB), 15 ependymomas (EP), 7 
glioblastoma multiforme (GBM), 6 atypical teratoid rhabdoid tumours (ATRT), 4 anaplastic astrocytomas (AA), 
4 choroid plexus papilloma (CPP), 3 gangliogliomas (GG), 2 atypical choroid plexus papillomas (ACPP), 2 CNS 
primitive neuroectodermal tumours (PNET), 1 choroid plexus carcinoma (CPC), 1 astroblastoma (AB) and 1 
unclassified low grade astrocytic glial tumour. As the tumour tissue was requested before the release of the WHO 
CNS classification 2016, diagnoses are those specified by the WHO CNS classification 200715. 35 patients died 
and 79 were alive at the end of the study. The median follow-up time for the whole cohort was 5.31 years (Table 1).
Sample preparation and HRMAS. The frozen samples were stored at −80 °C until used for HR-MAS. 
Samples were dissected on dry ice and inserted into either a 12 μl or 50 μl HR-MAS rotor with TMSP (Cambridge 
Biosciences, Cambridge, UK) as a quantification reference and D2O (Sigma-Aldrich, Dorset, UK) to fill the 
allocated rotor volume. Sample weights ranged from 3.4 to 35.8 mg. HR-MAS experiments were performed 
using a Bruker Avance 500 MHz (11.74 T) NMR spectrometer and a 4 mm 3 channel HR-MAS z-PFG band 
probe (Bruker, Coventry, UK). The samples were maintained at a temperature of 4 °C, a spin rate of 4800 Hz set for 
each experiment with 256 or 512 scans acquired depending on the signal-to-noise ratio. A standard 1D NOESY 
pulse sequence preceded by 2 s of water presaturation was acquired, with a repetition time of 4 s. In addition, a 
285 ms Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence was also acquired for each sample to aid in metabo-
lite identification by minimizing broad signal contributions from lipids and macromolecules.
Pilocytic 
astrocytoma
Medullo-
blastoma
Ependy-
moma
Gliobla-
stoma
Atypical teratoid 
rhabdoid 
tumour
Anaplastic 
astrocytoma
Choroid 
plexus 
papilloma
Ganglio-
glioma
CNS primitive 
neuroectodermal 
tumour
Atypical 
choroid plexus 
papilloma
Choroid 
plexus 
carcinoma
Astrobla-
stoma
Astrocytic 
glial 
tumour Total
N 36 32 15 7 6 4 4 3 2 2 1 1 1 114
Number of 
events (n) 3 13 3 6 4 3 0 0 1 1 1 0 0 35
Gender 
(male:female) 18:18 26:6 11:4 5:2 4:2 1:3 4:0 1:2 1:1 1:1 1:0 0:1 1:0 74:40
Mean age at 
diagnosis (years) 8.30 7.11 5.53 5.68 1.10 10.49 3.40 11.07 7.24 2.95 5.09 10.18 11.58 5.93
Age range 
(years) 1.2–15.9 1.5–14.6 0.3–16.3
0.03–
11.5 0.02–4.6 4.1–15.5 0.4–10.1 8.7–14.9 2.2–12.3 1.6–4.3 N/A N/A N/A 0.03–16.3
Median survival 
(years) 4.71 1.82 1.68 0.94 0.31 1.54 N/A N/A 0.94 1.93 1.39 N/A N/A 1.50
Anatomical  
location (n) 
[supratentorial: 
infratentorial: 
spinal]
7:29:0 0:32:0 5:9:1 6:1:0 1:5:0 3:1:0 2:2:0 2:1:0 2:0:0 1:1:0 1:0:0 1:0:0 0:1:0 31:82:1
Table 1. Clinical information for patients included in this study, organised by tumour diagnosis.
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Processing of HR-MAS data. Each free induction decay was Fourier transformed using TOPSPIN (Bruker, 
Coventry, UK). Phase and baseline correction (Whittaker Smoother) were performed using Mnova NMR 9.0 
software suite (2014; Mestrelab Research, Spain). Creatine was used as a chemical shift reference at 3.03 ppm. 
Spectral fitting was then performed between 0.5 and 4.7 ppm. All spectral peaks were deconvoluted and peak 
integrals measured followed by normalization to TMSP. The following metabolites were quantified and included 
in the analyses: acetate (Ace), alanine (Ala), ascorbate (Asc), choline (Cho), creatine (Cr), gamma-aminobutyric 
acid (GABA), glucose (Glc), glutamine (Gln), glutamate (Glu), glutathione (GSH), glycine (Gly), glycerophos-
phocholine (GPC), hypotaurine (hTau), isoleucine (Iso), lactate (Lac), leucine (Leu), myo-inositol (mIns), 
N-acetylaspartate (NAA), phosphocholine (PCh), serine (Ser), scyllo-inositol (sIns), succinate (Suc), taurine 
(Tau), valine (Val), lipids at 0.9 and lipids at 1.3 ppm (Fig. 1, Supplementary Table 1). Lipids were highly cor-
related, and so the lipid resonances were summed and termed total lipids. Metabolites were assigned according 
to Govindaraju et al.16 whilst lipids were assigned according to Moestue et al.17. Metabolite concentrations were 
normalised to the total sum of non-lipid metabolite concentrations.
Data and statistical analysis. Death caused by the tumour was the endpoint for the study, with time to 
event calculated from the date of first surgical resection to death. Univariate and multivariate Cox regression 
were performed on normalised metabolite concentrations and clinical parameters to determine the association 
of metabolites with survival. Likelihood ratio tests were used to determine significance of Cox models. Clinical 
parameters found to significantly predict survival in the univariate analyses were included as variables in the 
Figure 1. Example spectrum with annotated metabolite resonances and splitting patterns. Not visible in this 
spectrum are NAA(s) at 2.01ppm, GABA(t) at 2.30ppm, GPC(s) at 3.23ppm, sIns(s) at 3.34ppm and Glc(d) at 
4.65ppm. Abbreviations: s, singlet; d, doublet; t, triplet; dd, doublet of doublets; m, multiplet; ppm, parts per 
million.
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multivariate analyses. Univariate P-values were corrected using Benjamini-Hochberg correction to control the 
false discovery rate.
Validation of the models was performed using leave-one-out cross-validation (LOOCV) of C-indices, as 
described in Braadland et al.8. For each individual i, a Cox proportional hazards model is created leaving i out. 
The coefficients, βi, generated are applied to i’s covariates, xi, to obtain a linear predictor ηi = βixi. This is repeated 
for all individuals in the analysis creating the vector η = η1, η2, η2…ηn, where n is the number of individuals. The 
resultant vector of linear predictors is used as a single covariate in a Cox proportional hazards model to calculate 
the C-index. Normalised metabolite concentrations were scaled by dividing each metabolite by its standard devi-
ation prior to univariate and multivariate analysis.
Kaplan-Meier analyses were used to test the difference in survival of patients with brain tumours separated 
into groups above and below 25%, 50% or 75% quantiles for significant metabolites in the whole cohort. To fur-
ther test the robustness of the biomarkers, the whole cohort was divided based on the date of tissue collection 
into an initial cohort (n = 23), comprised of tissue collected during or before June 2006, and a validation cohort 
(n = 91), comprised of tissue collected after June 2006. The quantile showing the most significant result was recal-
culated in the initial cohort and the obtained value was applied to the validation cohort. Kaplan-Meier analysis 
was performed using logrank tests. All survival analyses were performed using the survival library written for the 
R software package18.
Results
Univariate cox regression. A total of 25 metabolite features were assigned as quantified using HR-MAS 
(Fig. 1, Supplementary Table 1). The mean metabolite concentrations for the different tumour groups are given 
in Supplementary Table 2. Univariate Cox regression identified 2 metabolites with prognostic potential (Table 2, 
Supplementary Table 3); higher Gln was associated with decreased risk of death, whilst a higher concentration 
of total lipids was associated with an increased risk of death. Whilst Val, Suc and hTau were significant in the 
univariate analysis, they were no longer significant upon P-value correction. Of the clinical features tested, diag-
nosis was shown to be a significant predictor of survival; patients diagnosed with AA, ATRT, CPC, GBM, MB 
and PNET had a significantly higher risk of death than PA patients (Table 2). Similar to Val, Suc and hTau, age at 
diagnosis was significant in the univariate analysis but was no longer significant after P-value correction. Gender 
and tumour location were not significant predictors of survival in this analysis (Supplementary Table 4).
Multivariate cox regression. The two metabolites with prognostic potential in the univariate analyses were 
further evaluated in a multivariate analysis. Each metabolite was assessed with diagnosis as a second covariate. 
Gln and total lipids were found to be predictors of survival independent of diagnosis, with higher concentrations 
of Gln predicting better survival, whilst higher concentrations of total lipids were associated with a higher risk of 
death (Table 2).
Validation of prognostic markers. Upon validation of the univariate analysis using leave one out cross 
validation of C-indices, total lipids alone demonstrated a marginally greater predictive accuracy than diagnosis 
alone. Validation of the multivariate models showed a greater predictive accuracy when either Gln or total lipids 
were combined with diagnosis when compared with diagnosis alone using the same validation method (Table 3).
The relationship between survival and metabolic predictors remained when the whole cohort was stratified 
into high and low concentrations groups using 25%, 50% and 75% quantiles. The difference in survival between 
patients with high and low Gln was greatest when cases were stratified by the 50% quantile Gln, whilst the dif-
ference between high and low lipids patients was greatest upon stratification using the 75% quantile (Fig. 2A,B). 
Variable
Univariate analysis Multivariate analyses
HR (95% CI) Corrected P-value
Glutamine model Total lipids model
HR (95% CI) P-value HR (95% CI) P-value
Gln 0.52 (0.31, 0.87) 0.041 0.42 (0.21–0.85) 0.015 — —
Total lipids 2.02 (1.53, 2.66) 2.48 × 10−4 — — 1.91 (1.35, 2.68) 2.15 × 10−4
Diagnosis 4.58 × 10−4
PA Reference — Ref — Ref —
AA 13.03 (2.62, 64.65) 0.0017 9.93(2.99, 49.59) 0.005 15.80 (3.16, 79.16) 7.86 × 10−4
ACPP 9.27 (0.95, 90.57) 0.056 3.41 (0.32, 36.58) 0.31 8.08 (0.82, 79.10) 0.073
ATRT 17.11 (3.80, 76.95) 2.1 × 10−4 8.63 (1.75, 42.61) 0.0081 11.69 (2.38, 57.53) 0.0025
CPC 35.46 (3.52, 357.31) 0.0025 9.48 (0.79, 113.46) 0.076 10.39 (0.96, 112.40) 0.054
EP 2.55 (0.51, 12.63) 0.25 1.34 (0.25, 7.09) 0.73 2.61 (0.53, 12.98) 0.24
GBM 31.72 (7.77, 129.45) 1.5 × 10−6 32.73 (7.86, 136.23) 1.64 × 10−6 22.29 (5.32, 93.31) 2.14 × 10−5
MB 5.91 (1.68, 20.76) 0.0056 2.45 (0.61, 9.89) 0.21 5.71 (1.62, 20.11) 0.0066
PNET 14.12 (1.44, 138.02) 0.023 6.03 (0.58, 63.08) 0.13 21.69 (2.15, 218.62) 0.009
Table 2. Univariate and multivariate Cox models for metabolite concentrations demonstrating their ability to 
predict overall survival of paediatric brain tumour patients. As no deaths were recorded for patients diagnosed 
with GG, AB, CPP or the unclassified glial tumour, these entries have been excluded from this table.
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Separation of the whole cohort into an initial cohort and validation cohort further demonstrated the prognostic 
ability of Gln and total lipids. The difference in survival using the 50% quantile Gln concentration in the initial 
cohort reached prognostic significance, which was maintained when the cut-off was applied to the validation 
cohort (Fig. 2C,D). The difference in survival using the 75% quantile total lipids in the initial cohort demon-
strated prognostic significance, which remained following application to the validation cohort (Fig. 2E,F).
Discussion
This study has shown that the concentration of metabolites measured in fresh, frozen diagnostic biopsy tissue 
from a variety of paediatric brain tumours using HR-MAS varies with disease aggressiveness. Through univariate 
and multivariate Cox models, it was shown that both Gln and total lipids have prognostic significance independ-
ent of tumour diagnosis and that addition of metabolite concentrations can aid in predicting overall survival. 
Interestingly, through cross-validation, total lipid concentration alone outperformed diagnosis in predicting sur-
vival, although the difference was small.
We have previously reported in vivo Gln concentration as a predictor of good prognosis in paediatric brain 
tumours independent of diagnosis6, and it is encouraging to have this confirmed by ex vivo spectroscopy. Gln 
is poorly resolved at an MR scanner field strength of 1.5 T due to the overlapping of signals from Glu, NAA 
and macromolecules. Techniques have been developed to improve the accuracy of Gln quantification; 1D MRS 
techniques include averaging spectra from different echo times (TE)19, the use of optimal TE’s20-22, very short 
TE’s23,24 and spectral-selective refocusing25. 2D techniques have also been developed but are not favoured due to 
the high level of expertise required to ensure reliable results and the time taken to acquire the data26. There have 
been recent advancements in ultrafast 2D NMR27, although this is still in its infancy. Overall, there is a realistic 
prospect that it will be possible to routinely measure tumour Gln levels in vivo in the near future.
Gln is the most abundant amino acid in blood plasma, and its metabolism has long been known to be impor-
tant in tumour biology28; uptake has been shown to increase in brain tumours in order to support cellular bio-
energetics and biosynthetic processes needed for proliferation29. Metabolism is under the direct control of major 
transcription factors such as TP53, Myc and Ras30. Mutations or changes in the regulation of these genes are 
common in cancers, including brain tumours, and switch the cells’ metabolism from oxidative phosphorylation 
of glucose to energy inefficient glucose fermentation and glutaminolysis31. This switch to Gln metabolism has 
been linked to poor prognosis32, therefore Gln concentration may aid stratification of patients into risk groups 
and inform treatment decisions. Due to the reliance of some cancers on Gln, the metabolism of this amino acid 
has been identified as a potential target for treatment33.
Lipids have also previously been identified as biomarkers of survival through in vivo MRS of paediatric brain 
tumours. The lipid signals can be generated by mobile lipids stored in cytoplasmic lipid droplets34,35 or by lipids 
in areas of tissue necrosis36,37, although it is unlikely that highly necrotic areas of tumour would be sampled. The 
role of lipids droplets in brain tumours is not well understood; however, there is evidence suggesting the number 
of lipid droplets increases in response to cellular stress and are associated with growth arrest38 and necrosis34. 
Furthermore, the number of cells positively stained for adipophilin, a lipid droplet associated protein, was shown 
to significantly increase with tumour grade39.
Risk stratification is not the only potential benefit of enhanced metabolite quantification. Progression of dis-
ease and response to treatment can be monitored using MRS. Increases in Gln concentration in contralateral 
white matter is linked to glioblastoma migration40, whilst reductions in the concentration of phosphocholine and 
lactate in glioblastoma cell lines have been observed after treatment with mTor and PI3K inhibitors41, reflecting 
the observation of reduced total Cho in orthotopic glioblastoma mouse models42. Increases in lipid concentra-
tions have been correlated with responses to treatment in cell lines exposed to chemotherapy agents38,43.
Suc, hTau and Val, which were significant in the univariate analysis before correction for multiple compar-
isons, warrant further investigation considering the limited understanding of these metabolites in the context 
of paediatric brain tumours. Increases in both Suc and hTau were associated with a longer survival time, whilst 
increases in Val were associated with a shorter survival time.
Despite in vivo studies identifying NAA and sIns as prognostic markers, neither metabolite reached prognos-
tic significance in the current study of tumour tissue. In addition to the limited sample size which could explain 
this, it is worth noting that the population of tumours included is somewhat different to that of in vivo studies 
and this could also contribute to the finding. There is a lack of available frozen tissue from surgically intractable 
tumours such as optic pathway gliomas and brain stem tumours unlike in vivo studies. Optic pathway gliomas 
have been shown to have a high concentration of NAA and a good prognosis whilst brain stem tumours have a 
higher concentration of sIns and a poor prognosis6.
In conclusion, this study has confirmed that the concentration of Gln and lipids in resected tissue are predic-
tors of survival independent of diagnosis. The importance of Gln and lipids as predictors of prognosis in children’s 
Variable
Univariate analysis Multivariate analysis
LOOCV C-index LOOCV C-index
Gln 0.641 0.686
Total lipids 0.670 0.727
Diagnosis 0.666 —
Table 3. Cross validation of the univariate and multivariate models demonstrate improved predictive accuracy after 
inclusion of either Gln or total lipid concentrations in addition to diagnosis when compared to diagnosis alone.
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tumours should lead to their measurement in tumour tissue, the implementation of MRS techniques to accurately 
measure their concentration non-invasively and the exploration of novel agents which can alter their metabolism 
for therapeutic effect.
Data Availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
Figure 2. Stratification of patients in the whole cohort into high and low metabolite concentration groups 
using (A) 50% quantile Gln and (B) 75% quantile total lipids demonstrates significant differences in survival. 
Stratification of patients in (C) the initial cohort using 50% quantile Gln demonstrates a significant difference in 
survival which remains upon application of the determined value to (D) the validation cohort. Stratification of 
patients in (E) the initial cohort using 75% quantile total lipids demonstrates a significant difference in survival 
which remains upon application of the determined value to (F) the validation cohort.
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